Compare Organon & Co. Common Stock (OGN) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Occidental Petroleum Corporation — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Occidental Petroleum Corporation trades at $61.76 (market cap $61.63B). The key difference: Occidental Petroleum Corporation is far larger — about 17× Organon & Co. Common Stock's market cap, and Occidental Petroleum Corporation pays the higher dividend (1.82%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Occidental Petroleum Corporation for 92 Days on average.
| OGN | OXY | |
|---|---|---|
Market Cap | $3.62B | $61.63B |
Volume | 2,892,999 | 9,180,422 |
Sector | Health | Energy |
52-Week High | $13.81 | $66.24 |
52-Week Low | $5.70 | $38.92 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $11.04B | $80.39B |
Dividend Yield | 0.58% | 1.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Occidental Petroleum (OXY) trades at $61.65, up 0.85% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $70.92. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Financials show strong profitability with a 30.32% net income margin and robust cash flow, though revenue has declined from 2022 peaks. Recent news highlights focus on dividend reliability and Goldman Sachs' upgrade citing cash flow targets and debt reduction.
OXY presents a favorable outlook with earnings momentum, attractive valuation multiples, and analyst support, but faces risks from oil price volatility and competitive pressures. The stock's upside potential hinges on execution of debt reduction and sustained operational efficiency amid energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
